Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622365 | 0.87 | MEN1 (0.40) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL24425859 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL13622352 | 0.83 | MEN1 (0.37) | MEN1KMT2APKML3MBTL1KDM4E | |
| SCHEMBL17816562 | 0.83 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL24425861 | 0.83 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL379262 | 0.82 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL5820577 | 0.82 | MEN1 (0.41) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL11859426 | 0.80 | MEN1 (0.41) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL11859437 | 0.80 | MEN1 (0.41) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL1026954 | 0.78 | MEN1 (0.46) | MEN1KMT2AALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-07-14 | — | — | US | disclosed |
| US-11331656-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331656-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | PPOX, CYBA, CYBB | MEN1 1935/4885KMT2A 3381/4885ALDH1A1 1395/4885 |
| US-20220219155-A1 | Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis | PPOX, CYBA, CYBB | MEN1 1935/4885KMT2A 3381/4885ALDH1A1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.